Abstract
The Gonadotropin-Releasing Hormone (GnRH) exists in two isoforms, GnRH-I and GnRH-II, in most vertebrates, including humans. Both of these isoforms and their respective receptors have been found in many healthy and pathologic extra nervous system tissues, such as cells found in cancers of the reproductive systems and, in particular, in breast cancer. GnRH analogues are used as therapeutic agents in the case of sex-hormone-dependent tumours. Besides acting as suppressors of steroidogenesis, GnRH analogues seem to interfere with mitogenic signal transduction pathways, thus behaving as negative regulators of tumour growth and progression.
GnRH analogues counteract the proliferating effects of both epidermal growth factor (EGF) and insulin like growth factor (IGF-I); additionally, it affects the mitogen-activated protein kinase (MAPK) cascade and modulates the activity of the urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitory (PAI) system, which is involved in the process of metastasis. In addition, GnRH analogues decrease the expression of many growth factors involved in the development of human uterine myomas (as well as endometriotic tissue), such as the vascular endothelial growth factor (VEGF), which is deeply implied in the angiogenesis of many benign and malignant tumours, including breast cancer.
Angiogenesis is one of the primary processes leading to the progression and metastasis of breast cancer cells, and a key therapeutic goal in the fight against tumours is the blocking of new vessel sprouts. Given these premises, this review provides an update on the background of anti-neoplastic properties of GnRH analogues..
Keywords: Angiogenesis, domestic animals, fibrosis, GnRH analogues, GnRH receptor, growth factors, kisspeptin, mammary tumours, metastasis, VEGF
Current Medicinal Chemistry
Title: The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Volume: 19 Issue: 7
Author(s): A. Rizzo, M. Spedicato, M. Mutinati, G. Minoia, R. Patruno, G. Ranieri and R. L. Sciorsci
Affiliation:
Keywords: Angiogenesis, domestic animals, fibrosis, GnRH analogues, GnRH receptor, growth factors, kisspeptin, mammary tumours, metastasis, VEGF
Abstract: The Gonadotropin-Releasing Hormone (GnRH) exists in two isoforms, GnRH-I and GnRH-II, in most vertebrates, including humans. Both of these isoforms and their respective receptors have been found in many healthy and pathologic extra nervous system tissues, such as cells found in cancers of the reproductive systems and, in particular, in breast cancer. GnRH analogues are used as therapeutic agents in the case of sex-hormone-dependent tumours. Besides acting as suppressors of steroidogenesis, GnRH analogues seem to interfere with mitogenic signal transduction pathways, thus behaving as negative regulators of tumour growth and progression.
GnRH analogues counteract the proliferating effects of both epidermal growth factor (EGF) and insulin like growth factor (IGF-I); additionally, it affects the mitogen-activated protein kinase (MAPK) cascade and modulates the activity of the urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitory (PAI) system, which is involved in the process of metastasis. In addition, GnRH analogues decrease the expression of many growth factors involved in the development of human uterine myomas (as well as endometriotic tissue), such as the vascular endothelial growth factor (VEGF), which is deeply implied in the angiogenesis of many benign and malignant tumours, including breast cancer.
Angiogenesis is one of the primary processes leading to the progression and metastasis of breast cancer cells, and a key therapeutic goal in the fight against tumours is the blocking of new vessel sprouts. Given these premises, this review provides an update on the background of anti-neoplastic properties of GnRH analogues..
Export Options
About this article
Cite this article as:
Rizzo A., Spedicato M., Mutinati M., Minoia G., Patruno R., Ranieri G. and L. Sciorsci R., The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals, Current Medicinal Chemistry 2012; 19 (7) . https://dx.doi.org/10.2174/092986712799320745
DOI https://dx.doi.org/10.2174/092986712799320745 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer
Current Medicinal Chemistry Template Synthesis of Tubular Nanostructures for Loading Biologically Active Molecules
Current Topics in Medicinal Chemistry Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Potential of Plant Mucilages in Pharmaceuticals and Therapy
Current Drug Delivery Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population
Current Genomics Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Current Gene Therapy Defective and Excessive Immunities in Pediatric Diseases
Current Pharmaceutical Design Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme
Current Medicinal Chemistry Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Metallothionein as a Negative Regulator of Pulmonary Inflammation
Current Pharmaceutical Biotechnology Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Inhibitor Binding Sites in the Protein Tyrosine Phosphatase SHP-2
Mini-Reviews in Medicinal Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Quantifying Serum Derived Differential Expressed and Low Molecular Weight Protein in Breast Cancer Patients
Protein & Peptide Letters